- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 22.12.25 | Gilead pays $35M to license pair of HSV assets from Assembly Bio pact | ||
| 22.12.25 | Boehringer spells out a $448M future for Rectify's ABC kidney disease program | ||
| 22.12.25 | Big Pharma-backed Aktis plans IPO to fund radiopharma trials | ||
| 22.12.25 | Novo Holdings-backed Windward buys rights to Qyuns' clinical-stage immunology bispecific in $700M deal | ||
| 22.12.25 | Ipsen continues ADC push with $1B deal for Simcere's preclinical LRRC15-targeting asset | ||
| 22.12.25 | AstraZeneca flunks phase 3 lung cancer test in further setback to synthetic lethal mechanism | ||
| 22.12.25 | AstraZeneca fronts $100M for Jacobio's clinical-stage pan-KRAS inhibitor | ||
| 19.12.25 | Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail | ||
| 19.12.25 | VC Aditum Bio launches new biotech in business play with Fosun Pharma | ||
| 19.12.25 | Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners | ||
| 19.12.25 | Altimmune eyes phase 3 MASH trial as weight loss deepens | ||
| 19.12.25 | Boehringer walks away from Nxera's phase 2-ready schizophrenia program | ||
| 18.12.25 | Verge Genomics drops sole clinical candidate in return to AI drug discovery roots | ||
| 18.12.25 | Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A | ||
| 18.12.25 | Patient deaths prompt partial hold for Daiichi-Merck's global phase 3 ADC program | ||
| 18.12.25 | Athira inks Sermonix deal to power ex-Pfizer asset toward phase 3 breast cancer data | ||
| 18.12.25 | After HHS funding was scrapped, CEPI fronts up to $54M to carry Moderna's pandemic influenza vaccine into phase 3 | ||
| 18.12.25 | Lilly's obesity pill largely maintains weight lost on injectable GLP-1s | ||
| 18.12.25 | Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success | ||
| 18.12.25 | GSK pays $17.5M to pitch its tent with CAMP4 in regulatory RNA deal | ||
| 17.12.25 | Voyager jettisons 30 employees, Novartis hands back rights to 2 programs | ||
| 17.12.25 | Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst | ||
| 17.12.25 | Fired NIH institute director sues Trump health officials, seeks reinstatement and backpay | ||
| 17.12.25 | Norgine gets in on Vir's hepatitis D program with €550 European licensing pact | ||
| 17.12.25 | Oncology biotech Mythic and former fundraising heavyweight Areteia reach end of road |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .